Liver Cancer - Obesity Reviews, Recent Papers, and Clinical Trials
To see all 18 Reviews, go directly to PubMed.
REVIEWS from PubMed – November 12, 2023 – Obesity (in title) AND Cancer (in title) AND Liver (in title) and Review
- Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis November 6, 2023CONCLUSION: Sarcopenia and sarcopenic obesity were significantly associated with poor overall survival and recurrence-free/disease-free survival in patients with primary liver cancer.Xuanmei Li
- Regional and sex differences in the mortality risk associated with primary liver cancer in obesity: A systematic review and meta-analysis July 5, 2023CONCLUSION: This study demonstrated a stronger association between obesity and PLC-related mortality in North America and Europe and among men.Long-Shan Yang
- Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression October 27, 2022Liver cancer is one of the most lethal malignancies and is commonly diagnosed as hepatocellular carcinoma (HCC), a tumor type that affects about 90% of patients. Non-alcoholic steatohepatitis (NASH) and obesity are both risk factors for this disease. HCC initiation and progression are deeply linked with changes in the hepatic microenvironment, with cytokines playing key […]Nathalia Soares da Cruz
- Obesity and Liver Cancer in Japan: A Comprehensive Review May 6, 2021Lifestyle-related factors play a major role in the development of cancer. In recent years, obesity has become widespread in the world and has attracted attention not only as a cause of diabetes mellitus and atherosclerotic diseases but also as a factor in carcinogenesis. In Japan, the number of obesity-related malignancies has been increasing with the […]Hiroki Nishikawa
- Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer March 6, 2021Obesity is rapidly dispersing all around the world and is closely associated with a high risk of metabolic diseases such as insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), leading to carcinogenesis, especially hepatocellular carcinoma (HCC). It results from an imbalance between food intake and energy expenditure, leading to an excessive accumulation of adipose […]Yetirajam Rajesh
- Obesity and the risk of primary liver cancer: A systematic review and meta-analysis November 25, 2020CONCLUSION: High BMI increases liver cancer mortality and occurrence of primary liver cancer. Obesity is an independent risk factor for the occurrence of and mortality from primary liver cancer.Won Sohn
- Obesity and liver cancer September 24, 2019Obesity prevalence is rapidly increasing worldwide. It is associated with huge economic and health costs due to its clinical consequences, which includes increased incidence of type 2 diabetes, cardiovascular diseases, and development of different malignancies. In particular, obesity is an independent risk factor for the development of hepatocellular carcinoma (HCC). Indeed, obesity is highly prevalent […]Carlo Saitta
- Treatment implications of natural compounds targeting lipid metabolism in nonalcoholic fatty liver disease, obesity and cancer July 31, 2019Metabolic disorders can lead to a scarcity or excess of certain metabolites such as glucose, lipids, proteins, purines, and metal ions, which provide the biochemical foundation and directly contribute to the etiology of metabolic diseases. Nonalcoholic fatty liver disease, obesity, and cancer are common metabolic disorders closely associated with abnormal lipid metabolism. In this review, […]Can Cheng
- Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer February 13, 2019Western populations are becoming increasingly sedentary and the incidence of nonalcoholic fatty liver disease (NAFLD) is increasing and becoming one of the most common causes of liver disease worldwide. Also, NAFLD is considered one the new emerging risk factors for development of tumors of the gastro-intestinal tract, particularly hepatocellular carcinoma (HCC). Visceral obesity is an […]Rosa Divella
- Obesity and Liver Cancer December 3, 2016Obesity and related metabolic disorders have become globally prevalent posing a challenge for the chronically damaged liver and predisposing the development and progression of cancer. The rising phenomenon of "obesity epidemic" may provide means for understanding why liver cancer is one of the few malignancies with rising incidence in developed countries over the last decades. […]Krasimira Aleksandrova
- Obesity and liver cancer: the roles of gut microbiota and cellular senescence November 18, 2015No abstractEiji Hara
- Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis October 17, 2015The burden of hepatocellular carcinoma (HCC), the most common form of liver cancer, is steadily growing because obesity, type 2 diabetes, and nonalcoholic fatty liver disease (NAFLD) are replacing viral- and alcohol-related liver disease as major pathogenic promoters. The most worrisome aspects of these new risk factors are their large spread in the general population […]Andrea Marengo
- Obesity and liver cancer November 27, 2013Obesity is an established risk factor for many types of cancers, particularly for hepatocellular carcinoma (HCC), owing to its carcinogenic potential and the association with nonalcoholic fatty liver disease (NAFLD). HCC may develop in cirrhotic and noncirrhotic livers with NAFLD, particularly in the presence of multiple metabolic risk factors such as obesity and diabetes. This […]Ester Vanni
- Non-viral causes of liver cancer: does obesity led inflammation play a role? September 7, 2013Liver cancer is the fifth most common cancer worldwide and the third most common cause of cancer mortality. Hepatocellular carcinoma (HCC) accounts for around 90% of primary liver cancers. Chronic infection with hepatitis B and hepatitis C viruses are two of most common causes of liver cancer. However, there are non-viral factors that are associated […]Badr Alzahrani
- Insulin resistance, obesity, and liver cancer August 20, 2013No abstractGeoffrey Farrell
- Obesity and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population January 14, 2012CONCLUSIONS: We conclude that overweight or obesity 'probably' increases the risk of primary liver cancer, to a moderate degree, among the Japanese population.Keitaro Tanaka
- Obesity, inflammation, and liver cancer November 29, 2011Obesity has become a universal and major public health problem with increasing prevalence in both adults and children in the 21st century, even in developing countries. Extensive epidemiological studies reveal a strong link between obesity and development and progression of various types of cancers. The connection between obesity and liver cancer is particularly strong and […]Beicheng Sun
- Obesity, fatty liver and liver cancer May 24, 2005CONCLUSIONS: Obesity is associated with the incidence and mortality of HCC. More frequent surveillance for HCC may be warranted in obese patients with fatty liver and attempts should be made to interrupt the progression from simple hepatic steatosis to steatohepatitis, cirrhosis and ultimately HCC.Yan Qian
To see all 51 Papers, go directly to PubMed.
RECENT PAPERS from PubMed – November 12, 2023 – Obesity (in title) AND Cancer (in title) AND Liver (in title)
- Association between obesity and liver cancer from 2012 to 2023: Bibliometric analysis and global trends August 2, 2024Incidence rates of liver cancer have increased worldwide in recent decades, making it a major public health problem globally. Obesity can be caused by multiple factors and promotes the development of liver cancer in many ways. Although the research on the association between obesity and liver cancer was previously explored, we first employed bibliometrics to […]Donghong Wang
- Impact of sarcopenia and sarcopenic obesity on survival in patients with primary liver cancer: a systematic review and meta-analysis November 6, 2023CONCLUSION: Sarcopenia and sarcopenic obesity were significantly associated with poor overall survival and recurrence-free/disease-free survival in patients with primary liver cancer.Xuanmei Li
- Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study October 10, 2023Several observational studies have reported an association between obesity and primary liver cancer (PLC), while the causality behind this association and the comparison of the risk effects of different obesity indicators on PLC remain unclear. In this study, we performed two-sample Mendelian randomization (MR) analyses to assess the associations of genetically determined liver fat, visceral […]Fei-Qi Xu
- Obesity control and liver health in breast cancer: Normalized hepatic elasticity after ketogenic diet October 2, 2023Most socially significant diseases, including breast cancer, are undeniably linked to obesity. Recently, a positive relationship between excessive weight and increased risk of breast cancer poor outcomes has been proved. Liver integrity is an essential point during chemotherapy. Consequently, a hepatic safe therapeutic approach for managing obesity in patients with breast cancer should be initiated. […]Aleksandar Georgiev
- Gut colonization with an obesity-associated enteropathogenic microbe modulates the premetastatic niches to promote breast cancer lung and liver metastasis July 28, 2023INTRODUCTION: Obesity, an independent risk factor for breast cancer growth and metastatic progression, is also closely intertwined with gut dysbiosis; and both obese state and dysbiosis promote each other. Enteric abundance of Bacteroides fragilis is strongly linked with obesity, and we recently discovered the presence of B. fragilis in malignant breast cancer. Given that enterotoxigenic […]Sheetal Parida
- Regional and sex differences in the mortality risk associated with primary liver cancer in obesity: A systematic review and meta-analysis July 5, 2023CONCLUSION: This study demonstrated a stronger association between obesity and PLC-related mortality in North America and Europe and among men.Long-Shan Yang
- Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression October 27, 2022Liver cancer is one of the most lethal malignancies and is commonly diagnosed as hepatocellular carcinoma (HCC), a tumor type that affects about 90% of patients. Non-alcoholic steatohepatitis (NASH) and obesity are both risk factors for this disease. HCC initiation and progression are deeply linked with changes in the hepatic microenvironment, with cytokines playing key […]Nathalia Soares da Cruz
- Obesity and Risk of Liver and Biliary Tract Cancer: Does Timing and Trajectory Matter? August 9, 2022No abstractChristie A Befort
- Risk Associations of Glycemic Burden and Obesity With Liver Cancer-A 10-Year Analysis of 15,280 Patients With Type 2 Diabetes January 19, 2022Liver is a major site for glucose metabolism. Patients with type 2 diabetes (T2D) and obesity have increased risk of liver cancer. We explored the association of glycemic burden (GB) and obesity with liver cancer in T2D in the prospective Hong Kong Diabetes Register (1995-2019). We calculated GB using the area under the curve above […]Dandan Mao
- Obesity and Liver Cancer in Japan: A Comprehensive Review May 6, 2021Lifestyle-related factors play a major role in the development of cancer. In recent years, obesity has become widespread in the world and has attracted attention not only as a cause of diabetes mellitus and atherosclerotic diseases but also as a factor in carcinogenesis. In Japan, the number of obesity-related malignancies has been increasing with the […]Hiroki Nishikawa
- Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity March 21, 2021CONCLUSION: Bariatric surgery was associated with significant reductions in the risks of any cancer and obesity-related cancer in NAFLD patients with severe obesity.Vinod K Rustgi
- Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer March 6, 2021Obesity is rapidly dispersing all around the world and is closely associated with a high risk of metabolic diseases such as insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD), leading to carcinogenesis, especially hepatocellular carcinoma (HCC). It results from an imbalance between food intake and energy expenditure, leading to an excessive accumulation of adipose […]Yetirajam Rajesh
- The role of visfatin and resistin in an in vitro model of obesity-induced invasive liver cancer December 28, 2020Obesity is associated with the development of liver disease and its progression to hepatocellular carcinoma. This link may be attributed to adipocytokines such as visfatin and resistin which have been shown to promote liver cancer incidence and progression. Studies have yet to determine the role of visfatin and resistin in liver cancer, specifically in the […]Candace Miethe
- Nod2 protects mice from inflammation and obesity-dependent liver cancer November 26, 2020Nod2 is a pattern recognition receptor that modulates host innate immune responses and protects from inflammation, steatosis, and obesity. Obesity and inflammation are risk factors for hepatocellular carcinoma, however, the role of Nod2 in obesity-dependent hepatic tumorigenesis is not known. Here we tested the hypothesis that Nod2 protects from high fat diet (HFD)-dependent hepatic cancer. […]Serdar A Gurses
- Obesity and the risk of primary liver cancer: A systematic review and meta-analysis November 25, 2020CONCLUSION: High BMI increases liver cancer mortality and occurrence of primary liver cancer. Obesity is an independent risk factor for the occurrence of and mortality from primary liver cancer.Won Sohn
- Fat mass and obesity-associated protein promotes the tumorigenesis and development of liver cancer July 30, 2020Liver cancer is the fourth leading cause of cancer-associated mortality worldwide. Statistics indicate that the incidence of liver cancer has been increasing and that its prognosis remains poor. Fat mass and obesity-associated protein (FTO) is a demethylase that is involved in N6-methyladenosine (m6a) RNA modification; however, to the best of our knowledge, its role in […]Ziqi Ye
- Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer June 12, 2020A 79-year-old man without a history of diabetes underwent orchiectomy for prostate cancer. Eight months after the operation, he suffered severe deterioration of visceral fat deposition, fatty liver and diabetes. Treatment for diabetes with canagliflozin and dulaglutide resulted in improvement in his glycemic control, visceral fat and fatty liver. Visceral fat-dominant deposition, which differs from […]Nobuo Kajitani
- Effect of Statin Use on Liver Cancer Mortality Considering Hypercholesterolemia and Obesity in Patients with Non-Cirrhotic Chronic Hepatitis B November 27, 2019Little is known about the benefits of statin use on liver cancer mortality among patients with chronic hepatitis B (CHB) considering hypercholesterolemia and obesity. A nationwide retrospective cohort study was conducted using data from a Health Examination Cohort of the National Health Insurance Service of Korea. Data on CHB patients with no other concurrent liver […]Gi Ae Kim
- Sarcopenic obesity in liver cancer: it is SO complicated November 2, 2019No abstractGyorgy Baffy
- Obesity and liver cancer September 24, 2019Obesity prevalence is rapidly increasing worldwide. It is associated with huge economic and health costs due to its clinical consequences, which includes increased incidence of type 2 diabetes, cardiovascular diseases, and development of different malignancies. In particular, obesity is an independent risk factor for the development of hepatocellular carcinoma (HCC). Indeed, obesity is highly prevalent […]Carlo Saitta
US Clinical Trials involving Liver Cancer and Obesity
| NCT Number | Study Title | Study URL | Acronym | Study Status | Interventions | Sponsor | Collaborators | Enrollment | Study Type | Locations |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT00344851 | Exenatide and Metformin Therapy in Overweight Women With PCOS | https://clinicaltrials.gov/study/NCT00344851 | COMPLETED | DRUG: metformin, exenatide or combined (metformin & exenatide ) | Metabolic Center of Louisiana Research Foundation | Amylin Pharmaceuticals, LLC. | 60 | INTERVENTIONAL | Facility: Metabolic Center of Louisiana Research Foundation, Baton Rouge, Louisiana, 70808, United States | |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma | https://clinicaltrials.gov/study/NCT03382886 | NUANCE | TERMINATED | DRUG: Nivolumab|DRUG: Bevacizumab | University of Utah | Bristol-Myers Squibb | 1 | INTERVENTIONAL | Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States |
| NCT01793168 | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | https://clinicaltrials.gov/study/NCT01793168 | CoRDS | RECRUITING | Sanford Health | National Ataxia Foundation|International WAGR Syndrome Association|4p- Support Group|ML4 Foundation|Cornelia de Lange Syndrome Foundation|Stickler Involved People|Kawasaki Disease Foundation|Klippel-Feil Syndrome Alliance|Klippel-Feil Syndrome Freedom|Hyperacusis Research Limited|Hypersomnia Foundation|Kabuki Syndrome Network|Kleine-Levin Syndrome Foundation|Leiomyosarcoma Direct Research Foundation|Marinesco-Sjogren Syndrome Support Group - NORD|Mucolipidosis Type IV (ML4) Foundation|People with Narcolepsy 4 People with Narcolepsy (PWN4PWN)|Soft Bones Incorporated|American Multiple Endocrine Neoplasia Support|Atypical Hemolytic Uremic Syndrome Foundation|All Things Kabuki|Wiedemann-Steiner Syndrome Foundation|Breast Implant Victim Advocates|PROS Foundation|American Behcet's Disease Association|Alstrom United Kingdom|Athymia|Curing Retinal Blindness Foundation|HSAN1E Society|1p36 Deletion Support and Awareness|The Alagille Syndrome Alliance|Autoinflammatory Alliance|Beyond Batten Disease Foundation|Bohring-Opitz Syndrome Foundation, INC|Cockayne Syndrome Network (Share and Care)|CRMO Foundation|Cure VCP Disease,INC|FOD Support|Cystinosis Research Foundation|Global DARE Foundation|Hypnic Jerk-Sleep Myoclonus Support Group|Jansen's Foundation|KCNMA1 Channelopathy International Advocacy Foundation|Kawasaki Disease Foundation Australia|Life with LEMS Foundation|Lowe Syndrome Association|The Malan Syndrome Foundation|Maple Syrup Urine Disease Family Support Group|International Association for Muscle Glycogen Storage Disease (IamGSD)|Myhre Syndrome Foundation|DNM1 Families|Nicolaides Baraitser Syndrome (NCBRS) Worldwide Foundation|The PBCers Organization|Pitt Hopkins Research Foundation|Progressive Familial Intrahepatic Cholestasis Advocacy and Resource Network, Inc|Recurrent Meningitis Association|Recurrent Respiratory Papillomatosis Foundation|Remember the Girls|Smith-Kingsmore Syndrome Foundation|SPG Research Foundation|Team Telomere|Transient Global Amnesia Project|The Charlotte & Gwenyth Gray Foundation|The Cute Syndrome Foundation|The Maddi Foundation|White Sutton Syndrome Foundation|Zmynd11 Gene Disorder|Cauda Equina Foundation, Inc|Tango2 Research Foundation|Noah's Hope - Hope4Bridget Foundation|Project Sebastian|SMC1A Epilepsy Foundation|International Foundation for Gastrointestinal Disorders|Endosalpingiosis Foundation, Inc|International Sacral Agenesis/Caudal Regression Association (ISACRA)|Scheuermann's Disease Fund|Batten Disease Support and Research Association|Kennedy's Disease Association|Cure Mito Foundation|Warburg Micro Research Foundation|Cure Mucolipidosis|Riaan Research Initiative|CureARS A NJ Nonprofit Corporation|CACNA1H Alliance|IMBS Alliance|SHINE-Syndrome Foundaion|Non- Ketotic Hyperglycinemia (NKH) Crusaders|Hypertrophic Olivary Degeneration Association (HODA)|National Organization for Disorders of the Corpus Callosum (NODCC) | 20000 | OBSERVATIONAL | Sanford Health, Sioux Falls, South Dakota, 57104, United States|Online Patient Enrollment System, Sydney, Australia | |
| NCT03041129 | Post-Prandial Liver Glucose Metabolism in PCOS | https://clinicaltrials.gov/study/NCT03041129 | PLUM | COMPLETED | DIAGNOSTIC_TEST: oral glucose tolerance test|DIAGNOSTIC_TEST: MRI of liver | University of Colorado, Denver | 19 | OBSERVATIONAL | University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora, Colorado, 80045, United States | |
| NCT05602194 | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | https://clinicaltrials.gov/study/NCT05602194 | RECRUITING | PROCEDURE: Biospecimen Collection|DRUG: Calaspargase Pegol|DIETARY_SUPPLEMENT: Levocarnitine|DRUG: Pegaspargase|OTHER: Quality-of-Life Assessment | Children's Oncology Group | 440 | INTERVENTIONAL | City of Hope Comprehensive Cancer Center, Duarte, California, 91010, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, 90806, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States|Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, 33021, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, 32207, United States|AdventHealth Orlando, Orlando, Florida, 32803, United States|Nemours Children's Hospital, Orlando, Florida, 32827, United States|Sacred Heart Hospital, Pensacola, Florida, 32504, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, 33607, United States|Riley Hospital for Children, Indianapolis, Indiana, 46202, United States|Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana, 46260, United States|Norton Children's Hospital, Louisville, Kentucky, 40202, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121, United States|Maine Children's Cancer Program, Scarborough, Maine, 04074, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, 48109, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Bronson Battle Creek, Battle Creek, Michigan, 49017, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, 49503, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, 49503, United States|Trinity Health Grand Rapids Hospital, Grand Rapids, Michigan, 49503, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States|West Michigan Cancer Center, Kalamazoo, Michigan, 49007, United States|Ascension Borgess Cancer Center, Kalamazoo, Michigan, 49009, United States|Borgess Medical Center, Kalamazoo, Michigan, 49048, United States|Trinity Health Muskegon Hospital, Muskegon, Michigan, 49444, United States|Lakeland Hospital Niles, Niles, Michigan, 49120, United States|Cancer and Hematology Centers of Western Michigan - Norton Shores, Norton Shores, Michigan, 49444, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, 49677, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, 49085, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, 49085, United States|Munson Medical Center, Traverse City, Michigan, 49684, United States|University of Michigan Health - West, Wyoming, Michigan, 49519, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Albany Medical Center, Albany, New York, 12208, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, 10467, United States|NYU Winthrop Hospital, Mineola, New York, 11501, United States|New York Medical College, Valhalla, New York, 10595, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, 27599, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, 44106, United States|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, 43606, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States|Saint Francis Hospital, Greenville, South Carolina, 29601, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, 29605, United States|Saint Francis Cancer Center, Greenville, South Carolina, 29607, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, 37203, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States|M D Anderson Cancer Center, Houston, Texas, 77030, United States|Covenant Children's Hospital, Lubbock, Texas, 79410, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, 79415, United States|Children's Hospital of San Antonio, San Antonio, Texas, 78207, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, 78229, United States|University of Virginia Cancer Center, Charlottesville, Virginia, 22908, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, 99204, United States|Mary Bridge Children's Hospital and Health Center, Tacoma, Washington, 98405, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, 54449, United States | ||
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation | https://clinicaltrials.gov/study/NCT02935478 | SUSPENDED | DEVICE: Embospheres Microspheres | St. Louis University | 8 | INTERVENTIONAL | Saint Louis University, Saint Louis, Missouri, 63110, United States | ||
| NCT03717935 | Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS | https://clinicaltrials.gov/study/NCT03717935 | ORANGE | COMPLETED | DIETARY_SUPPLEMENT: Essential Amino Acid (EAA) Supplement|OTHER: Placebo | University of Colorado, Denver | 27 | INTERVENTIONAL | University of Colorado, Anschutz Medical Campus, Aurora, Colorado, 80045, United States | |
| NCT01047735 | The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes | https://clinicaltrials.gov/study/NCT01047735 | TRIABETES | ACTIVE_NOT_RECRUITING | PROCEDURE: Roux-en-Y Gastric Bypass Surgery|PROCEDURE: Laparoscopic Adjustable Gastric Banding|BEHAVIORAL: Lifestyle Weight Loss Intervention | University of Pittsburgh | National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 69 | INTERVENTIONAL | William F Gourash, Pittsburgh, Pennsylvania, 15213, United States |
| NCT04540081 | Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer | https://clinicaltrials.gov/study/NCT04540081 | CLOVER | RECRUITING | OTHER: Epic Healthy Planet Population Health Module | University of California, Davis | University of California, Irvine | 20000 | INTERVENTIONAL | UC Davis Medical Center, Sacramento, California, 95817, United States |
| NCT02157974 | Liver and Fat Regulation in Overweight Adolescent Girls | https://clinicaltrials.gov/study/NCT02157974 | APPLE | COMPLETED | DRUG: Byetta 5Mcg Pen Injection | University of Colorado, Denver | National Center for Advancing Translational Sciences (NCATS) | 92 | INTERVENTIONAL | University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora, Colorado, 80045, United States |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial | https://clinicaltrials.gov/study/NCT02431676 | SPIRIT | COMPLETED | DRUG: Metformin|BEHAVIORAL: Coach Directed Behavioral Weight Loss|BEHAVIORAL: Self-control weight loss | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Maryland Cigarette Restitution Fund | 121 | INTERVENTIONAL | Johns Hopkins ProHealth, Baltimore, Maryland, 21207, United States |